Abstract
Background: Esophageal Squamous Cell Carcinoma (ESCC) is a common malignant tumor in China, which causes about 200,000 deaths each year. Sensitive biomarkers are helpful to diagnose the disease in early stage.
Methods: To identify biomarkers of ESCC and elucidate underlying mechanism of the disease, a targeted metabolomics strategy based on liquid chromatography-tandem mass spectrometry (LCMS/ MS) has been implemented to explore tyrosine metabolism from 40 ESCC patients and 27 healthy controls.
Results: Four metabolites, i.e. phenylalanine, 4-hydroxyphenyllactic acid, 3,4-dihydroxyphenylalanine, and 3,4-dihydroxyphenylacetic acid were identified as diagnostic biomarkers for ESCC patients. Based on these biomarkers, a prediction model was constructed for ESCC diagnosis. The analysis of receiver operating characteristic (ROC) curve confirmed its effectiveness of the model.
Conclusion: Our results reveal that tyrosine metabolism is disturbed in ESCC patients and the metabolites involved in tyrosine pathway can be used as diagnostic biomarkers of the disease. Findings of this study can help investigate pathogenesis of ESCC and facilitate understanding mechanism of the disease.
Keywords: ESCC, metabolomics, LC-MS/MS, tyrosine metabolism, diagnostic biomarker, prediction model.
Combinatorial Chemistry & High Throughput Screening
Title:Towards Tyrosine Metabolism in Esophageal Squamous Cell Carcinoma
Volume: 20 Issue: 2
Author(s): Jing Cheng, Guangyong Zheng*, Hai Jin and Xianfu Gao*
Affiliation:
- Key Laboratory of Computational Biology, CAS-MPG Partner Institute for Computational Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 200031,China
- Key Laboratory of Systems Biology, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 200031,China
Keywords: ESCC, metabolomics, LC-MS/MS, tyrosine metabolism, diagnostic biomarker, prediction model.
Abstract: Background: Esophageal Squamous Cell Carcinoma (ESCC) is a common malignant tumor in China, which causes about 200,000 deaths each year. Sensitive biomarkers are helpful to diagnose the disease in early stage.
Methods: To identify biomarkers of ESCC and elucidate underlying mechanism of the disease, a targeted metabolomics strategy based on liquid chromatography-tandem mass spectrometry (LCMS/ MS) has been implemented to explore tyrosine metabolism from 40 ESCC patients and 27 healthy controls.
Results: Four metabolites, i.e. phenylalanine, 4-hydroxyphenyllactic acid, 3,4-dihydroxyphenylalanine, and 3,4-dihydroxyphenylacetic acid were identified as diagnostic biomarkers for ESCC patients. Based on these biomarkers, a prediction model was constructed for ESCC diagnosis. The analysis of receiver operating characteristic (ROC) curve confirmed its effectiveness of the model.
Conclusion: Our results reveal that tyrosine metabolism is disturbed in ESCC patients and the metabolites involved in tyrosine pathway can be used as diagnostic biomarkers of the disease. Findings of this study can help investigate pathogenesis of ESCC and facilitate understanding mechanism of the disease.
Export Options
About this article
Cite this article as:
Cheng Jing, Zheng Guangyong*, Jin Hai and Gao Xianfu*, Towards Tyrosine Metabolism in Esophageal Squamous Cell Carcinoma, Combinatorial Chemistry & High Throughput Screening 2017; 20(2) . https://dx.doi.org/10.2174/1386207319666161220115409
DOI https://dx.doi.org/10.2174/1386207319666161220115409 |
Print ISSN 1386-2073 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5402 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Laminin-332-Integrin Interaction: A Target For Cancer Therapy?
Current Medicinal Chemistry On the Nature of the Tumor-Initiating Cell
Current Stem Cell Research & Therapy Advances in Interleukin-12 Gene Therapy for Acquired Liver Diseases
Current Gene Therapy Is Effective and Safe a Radiochemotherapy Approach in Elderly Cancer Patients? A Review
Anti-Cancer Agents in Medicinal Chemistry Prognostic Markers in Small Cell Lung Cancer
Current Cancer Therapy Reviews Membrane Transporters as Determinants of the Pharmacology of Platinum Anticancer Drugs
Current Cancer Drug Targets Current Status of SUMOylation Inhibitors
Current Medicinal Chemistry Anti-cancer Peptides from Ras-P21 and P53 Proteins
Current Pharmaceutical Design Matrix Metalloproteinases in Respiratory Diseases: From Pathogenesis to Potential Clinical Implications
Current Medicinal Chemistry Targeting Transcription Factors for Cancer Gene Therapy
Current Gene Therapy Smoking is Associated with Lung Adenocarcinoma and Lung Squamous Cell Carcinoma Progression through Inducing Distinguishing lncRNA Alterations in Different Genders
Anti-Cancer Agents in Medicinal Chemistry Nanomaterials in the Pharmaceuticals: Occurrence, Behaviour and Applications
Current Pharmaceutical Design A Proteomic Approach To Porcine Saliva
Current Protein & Peptide Science Targeting Vascular Niche by Parathyroid Hormone
Current Medicinal Chemistry An Overview on Fibroblast Growth Factors: Structural, Functional and Therapeutic Implications
Current Proteomics Pleiotrophin as a Possible New Target for Angiogenesis-Related Diseases and Cancer
Recent Patents on Anti-Cancer Drug Discovery Platinum(II) and Palladium(II) Complex Compounds as Anti-cancer Drugs. Methods of Cytotoxicity Determination
Current Pharmaceutical Analysis Histone Modifications as Molecular Targets in Nasopharyngeal Cancer
Current Medicinal Chemistry Vascular Injury During Elevated Glucose can be Mitigated by Erythropoietin and Wnt Signaling
Current Neurovascular Research Targeting Tumors with Small Molecule Peptides
Current Cancer Drug Targets